Emcure Pharmaceuticals IPO: Check Issue Date, Price, Lot Size & Company Financial

IPO Details

Bidding Dates

To be announced

Minimum Investment

To be announced

Price Range

To be announced

Maximum Investment

To be announced

Retail Discount

To be announced

Issue Size

up to [●] equity shares aggregating up to ₹8,000 million

Investor category and sub category

Retail Individual Investors (RII) | Non-institutional Investors (NII) | Qualified Institutional Buyers (QIB) | Eligible employees |

About Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited is a notable figure within India's pharmaceutical sector, renowned for its extensive research, development, and worldwide distribution of a wide array of pharmaceutical products. With a diverse portfolio encompassing oral medications, injectables, and biotherapeutics, the company caters to over 70 countries, with a particular focus on markets in India, Europe, and Canada. They have a strong standing in critical market segments such as gynaecology, HIV antivirals, and cardiovascular drugs.

The company's growth trajectory is defined by significant milestones, including rapid sales expansion in India and a substantial global presence. Emcure has demonstrated expertise in chronic therapeutic areas, anticipating considerable growth opportunities and cultivating a range of high-performing brands both domestically and internationally.

The organisation's vertically integrated manufacturing capabilities ensure cost-efficiency, quality control, and strategic advantages in key product segments like injectables, iron products, and biotherapeutics.

Industry Outlook:

With India emerging as one of the fastest-growing large economies, poised to grow at 6.1% in 2023 and 6.3% in 2024.
Despite global market moderation, the pharmaceutical sector is projected to sustain a steady 4.5-5% CAGR from 2022 to 2027.

Emcure Pharmaceuticals Limited IPO Details

Emcure Pharmaceuticals Limited IPO Dates

The exact dates are yet to be announced.

Emcure Pharmaceuticals Limited IPO Price Band

The Prize band is yet to be announced

Emcure Pharmaceuticals Limited IPO Lot Size

The exact lot size is yet to be announced.

Emcure Pharmaceuticals Limited IPO Objectives

The company plans to allocate the net proceeds from the issuance to the following purposes:

Utilise ₹6,400.00 million from Net Proceeds to repay or prepay outstanding borrowings, ensuring reduced debt and interest burdens for the company.
Allocate the remaining Net Proceeds for general corporate objectives like funding growth opportunities, marketing, capital expenditure, investment in subsidiaries, and addressing corporate contingencies.

Peer Details

The following are the listed peers of Emcure Pharmaceuticals Limited:

Dr. Reddy's Laboratories Limited
Cipla Limited
Alkem Laboratories Limited
Torrent Pharmaceuticals Limited
Mankind Pharma Limited
Abbott India Limited

How to Check the Allotment Status of the Emcure Pharmaceuticals Limited IPO?

Steps to check IPO allotment status on Angel One’s app:

Log in to the Angel One app
Go to the IPO Section and then to IPO Orders.
Select the individual IPO that you had applied for and check the allotment status.
Angel One will notify you of your IPO allotment status via push notification and email.

Contact Details of Emcure Pharmaceuticals Limited IPO

Registered office: Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune 411 057, Maharashtra, India
Phone: +91 20 3507 0033, +91 20 3507 0000
E-mail:investors@emcure.com

IPO Financials

Particulars	As of September 30,2023	Year ending on March 31, 2023	Year ending on March 31, 2022	Year ending on March 31, 2021
Revenue from Operations (in ₹ Million)	32,192.51	59,858.11	58,553.87	50,334.74
Profit After Tax (PAT) (in ₹ million)	2,868.01	5,618.45	7,025.56	4,185.94
Cash and Cash Equivalents (in ₹ Million)	3,442.93	2,423.42	1,628.49	4,687.46
Return on Net Worth (%)	9.80	21.27	33.32	17.25
Net Debt (in ₹ million)	14,632.99	17,149.63	17,541.08	17,886.98
Return on Equity (%)	9.84	21.20	33.23	17.68
Return on Capital Employed (RoCE) (%)	11.43	22.01	29.69	20.58
EBITDA (in ₹ million)	6,378.31	12,209.41	13,933.81	11,787.69

Know before investing

Strengths

Emcure's strong focus on the Indian market, accounting for over half of its revenue, has propelled it to a top position in key therapeutic areas like gynaecology and HIV antivirals, showcasing significant growth potential and market dominance.
With a presence in over 70 countries, particularly in Europe and Canada, Emcure's diversified product portfolio offers ample growth opportunities internationally, contributing significantly to its overall revenue.
Emcure's robust in-house R&D expertise enables the development of a differentiated product range, including complex molecules, novel drug delivery systems, and biotherapeutics, providing the company with a competitive advantage.

Risks

Emcure Pharmaceuticals Limited faces the risk of non-compliance with regulatory requirements and quality standards. Failure to comply may lead to regulatory actions such as restrictions on product sales, recalls, civil penalties, or criminal prosecutions, which could significantly impact the company's reputation and financial stability.
The company is exposed to product liability claims due to potential quality issues in its products. Product recalls or failure to meet quality standards can result in financial losses, legal proceedings, and damage to Emcure's brand image.
As a highly regulated industry participant, Emcure must obtain and maintain various regulatory licences, permits, and approvals. Changes in regulatory requirements or new laws could further increase compliance challenges for the company.
Emcure faces operational risks related to manufacturing and research activities. Any disruptions, shutdowns, or delays in operations due to equipment failures, accidents, or regulatory disputes could impact production, fulfilment of contractual commitments, and overall business performance.